Transdermal hormone therapy and bone health

Lee P ShulmanDivision of Reproductive Genetics, Department of Obstetrics and Gynecology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois, USAAbstract: The clinical aftermath of the reporting of the initial findings of the Women’s Health Initiative (WHI) in 2002 wa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Lee P Shulman
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/8334c8be3f4a45ea926aee7c06e1f5b8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8334c8be3f4a45ea926aee7c06e1f5b8
record_format	dspace
spelling	oai:doaj.org-article:8334c8be3f4a45ea926aee7c06e1f5b82021-12-02T03:41:38ZTransdermal hormone therapy and bone health1178-1998https://doaj.org/article/8334c8be3f4a45ea926aee7c06e1f5b82008-03-01T00:00:00Zhttps://www.dovepress.com/transdermal-hormone-therapy-and-bone-health-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Lee P ShulmanDivision of Reproductive Genetics, Department of Obstetrics and Gynecology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois, USAAbstract: The clinical aftermath of the reporting of the initial findings of the Women’s Health Initiative (WHI) in 2002 was a profound reduction in the use of hormone therapies by menopausal women. This reduction led to a well documented increase in vasomotor symptoms and vaginal atrophy among those women who discontinued their hormone regimens. However, another adverse impact among these women, as well as many other menopausal women, is the well recognized increased likelihood of osteoporosis resulting from the decline in circulating estradiol levels associated with natural and surgical menopause. Although the use of non-hormonal drugs such as bisphosphonates has been shown to reduce the risk of fracture in women with osteoporosis, bisphosphonates have not been shown to reduce the risk of fracture in non-osteoporotic women. Indeed, only oral estrogen (as demonstrated in the WHI studies) has been shown to reduce the risk of fracture in osteoporotic and non-osteoporotic women. As non-oral hormone therapies have been shown to be as effective in treating vasomotor symptoms and vulvovaginal atrophy and to have a different (and perhaps more beneficial) physiological effect than oral regimens, it behooves us to assess the impact of non-oral hormone regimens on bone mineral density and fracture risk. Although there are no clinical trials that primarily assess the impact of non-oral regimens on fracture risk in menopausal women, numerous studies are consistent in demonstrating the positive impact of non-oral regimens in maintaining and increasing bone mineral density among users, even for those women using estrogen doses that are considered to be “too low” to have a beneficial impact on other menopausal symptoms.Keywords: menopause, hormone, estrogen, non-oral, bone, osteoporosis, fractureLee P ShulmanDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 51-54 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Lee P Shulman Transdermal hormone therapy and bone health
description	Lee P ShulmanDivision of Reproductive Genetics, Department of Obstetrics and Gynecology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois, USAAbstract: The clinical aftermath of the reporting of the initial findings of the Women’s Health Initiative (WHI) in 2002 was a profound reduction in the use of hormone therapies by menopausal women. This reduction led to a well documented increase in vasomotor symptoms and vaginal atrophy among those women who discontinued their hormone regimens. However, another adverse impact among these women, as well as many other menopausal women, is the well recognized increased likelihood of osteoporosis resulting from the decline in circulating estradiol levels associated with natural and surgical menopause. Although the use of non-hormonal drugs such as bisphosphonates has been shown to reduce the risk of fracture in women with osteoporosis, bisphosphonates have not been shown to reduce the risk of fracture in non-osteoporotic women. Indeed, only oral estrogen (as demonstrated in the WHI studies) has been shown to reduce the risk of fracture in osteoporotic and non-osteoporotic women. As non-oral hormone therapies have been shown to be as effective in treating vasomotor symptoms and vulvovaginal atrophy and to have a different (and perhaps more beneficial) physiological effect than oral regimens, it behooves us to assess the impact of non-oral hormone regimens on bone mineral density and fracture risk. Although there are no clinical trials that primarily assess the impact of non-oral regimens on fracture risk in menopausal women, numerous studies are consistent in demonstrating the positive impact of non-oral regimens in maintaining and increasing bone mineral density among users, even for those women using estrogen doses that are considered to be “too low” to have a beneficial impact on other menopausal symptoms.Keywords: menopause, hormone, estrogen, non-oral, bone, osteoporosis, fracture
format	article
author	Lee P Shulman
author_facet	Lee P Shulman
author_sort	Lee P Shulman
title	Transdermal hormone therapy and bone health
title_short	Transdermal hormone therapy and bone health
title_full	Transdermal hormone therapy and bone health
title_fullStr	Transdermal hormone therapy and bone health
title_full_unstemmed	Transdermal hormone therapy and bone health
title_sort	transdermal hormone therapy and bone health
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/8334c8be3f4a45ea926aee7c06e1f5b8
work_keys_str_mv	AT leepshulman transdermalhormonetherapyandbonehealth
_version_	1718401675833638912

Transdermal hormone therapy and bone health

Ejemplares similares